June 3, 2014 Welcome to the Seventh Massachusetts Life Sciences Innovation Day! Once again, we bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to mingle with innova- tors, post-docs, professors, entrepreneurs, innovators, and venture capitalists. This is the big- gest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This year’s theme is “Can you still be creative?” Our speakers and panelists will consider how researchers in both academia and industry can still be creative in their scientific endeavors. Our speakers and panelists have years of experience and represent a wide range of technologies and inventions. They are presidents, CEOs, investors and consultants of leading companies and institutions throughout the area. We hope you find their discussions thought provoking. The Poster Competition includes some of the greatest and newest ideas that could impact medi- cine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced by State Senator Karen Spilka during our ever popular evening reception attended by many CEOs who have taken on the judging of the posters. Don’t miss the opportunity to speak with them and discuss your projects. We are particularly grateful to our Planning Committee for their help, support and entrepreneur- ial spirit in organizing this event. We would also like to thank all of our sponsors, particularly Pepper Hamilton and the Massachusetts Life Sciences Center, our lead sponsors for this event. All of our sponsors are as committed as we are to supporting the creation of new companies and we are grateful to them all. We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sci- ences start-up ecosystem in the Commonwealth. Dr. Abigail A. Barrow Chair MALSI Director, Massachusetts Technolgy Transfer Center
Transcript
June 3, 2014
Welcome to the Seventh Massachusetts Life Sciences Innovation Day!
Once again, we bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to mingle with innova-tors, post-docs, professors, entrepreneurs, innovators, and venture capitalists. This is the big-gest day for life sciences startups and innovation in the Commonwealth of Massachusetts.
This year’s theme is “Can you still be creative?” Our speakers and panelists will consider how researchers in both academia and industry can still be creative in their scientific endeavors. Our speakers and panelists have years of experience and represent a wide range of technologies and inventions. They are presidents, CEOs, investors and consultants of leading companies and institutions throughout the area. We hope you find their discussions thought provoking.
The Poster Competition includes some of the greatest and newest ideas that could impact medi-cine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced by State Senator Karen Spilka during our ever popular evening reception attended by many CEOs who have taken on the judging of the posters. Don’t miss the opportunity to speak with them and discuss your projects.
We are particularly grateful to our Planning Committee for their help, support and entrepreneur-ial spirit in organizing this event. We would also like to thank all of our sponsors, particularly Pepper Hamilton and the Massachusetts Life Sciences Center, our lead sponsors for this event. All of our sponsors are as committed as we are to supporting the creation of new companies and we are grateful to them all.
We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sci-ences start-up ecosystem in the Commonwealth.
Dr. Abigail A. BarrowChair MALSIDirector, Massachusetts Technolgy Transfer Center
7th AnnualMassachusetts Life Sciences Innovation Day
ii
Table of ContentsFloor Plan – Harvard Club of Boston ...............................................................................................iii
Richard AndersFounder, Managing Director, Mass Medical Angels
Richard Anders is a long-time entrepreneur. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and is currently managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects. He served for many years as a member of the Institutional Review Board at the Dana Far-ber Cancer Center, and was a long-time trustee of the Museum of Science, where he currently is an overseer. Richard founded and currently runs MA Medical Angels (MA2), one of the country’s leading angel groups focused exclusively on life sciences. He founded the angel group Launchpad, the nationally renowned Sci-ence on Screen event at the Coolidge Corner Cinema, and was a founding trustee of the Massachusetts Interactive Media Council. He is a board observer at Avaxia Biologics and Sialix and an overseer at the Gardner Museum. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.
Robert AndersonPartner, Lathrop & Gage LLP
With more than 23 years in the field of biotechnology, Bob Anderson focuses his practice on intellectual prop-erty assessment, protection, licensing and commercialization of novel therapeutics. His experience includes bringing innovative biotechnology from concept to commercialization.
Bob Anderson has extensive experience in global transactional law including technology transfer, licensing, collaborative research and clinical trial agreements as well as mergers and acquisitions. His international experience includes both Europe and Japan.
Most recently, Mr. Anderson was responsible for licensing and developing all global pharmaceutical products and clinical candidates for Abbott Laboratories, a Fortune 100 global healthcare company. He was a key player in acquiring, protecting and enabling Abbott Laboratories’ pharmaceutical products pipeline, particu-larly in the areas of biologics research and development, manufacture and commercialization, including Ab-bott’s drug, HUMIRA®, the first fully human therapeutic antibody.
Mr. Anderson also formerly served as General Counsel for BASF Bioresearch Corporation (BASF is an in-ternational Fortune 100 corporation). Bob was a founding member of BASF Bioresearch Corporation’s man-agement team, which built a world-class research, development and biologics manufacturing organization from 10 employees up to approximately 700 scientists, clinicians, engineers, and professional staff. He was also a key member of the BASF legal team that finalized the $6.9 Billion acquisition of Knoll AG (BASF AG’s worldwide pharmaceutical company) by Abbott.
7th AnnualMassachusetts Life Sciences Innovation Day
10 Biographies
Jeffrey ArnoldCEO, Arnold Strategies, LLC
Mr. Arnold is the CEO of Arnold Strategies, LLC, which assists early stage and growth companies in strategy, marketing, financing, organizational development and strategic partnerships. He was formerly the CEO of multiple technology and life science companies who raised over $140 million in venture capital and public financings and achieved four exits through acquisition and IPO. Mr. Arnold is a mentor to early stage com-panies at the MIT Venture Mentoring Society, on the grant review board at the MIT Deshpande Center and an investor with Boston Harbor Angels and Mass Medical Angels. He was formerly Chairman of the Greater Boston Chapter of the American Heart Association. He received a BSEE from MIT in 1972.
Stamatis AstraCEO, PhotOral Inc.
Stamatis N. Astra is the founder and CEO of Boston-based PhotOral, a life science startup focused on commercializing photo-medicine technology for the oral care market. PhotOral has entered into a commer-cial partnership with a global health care company to bring to market its first product. Astra’s early career brimmed with startup experience ranging from ‘dot-com’ VOIP software firm, TeleGea, where he built a global customer network from Tokyo to Brazil as Vice President of Technology - to more recently, the online identity theft solutions-based startup identityTruth, which he co-founded and later sold. Astra served as the CEO of a multinational manufacturer listed on Canada Stock Exchange before returning to the startup world. Astra holds a BS in Economics magna cum laude as well as an MBA and MS in Communications Management-also with honors and all from Boston University. Astra is Chairman of Development for Boston University’s Arion Journal of Humanities and The Classics, and hosts his talk show on WNTN-1550 AM for a Greek-American audience in Boston. A staunch community service advocate, Astra lends his business expertise to numerous organizations and charities in New England and in Athens, Greece.
Kenneth AttieVP, Medical Research, Acceleron
Dr. Attie joined Acceleron in December 2009 and is Vice President of Medical Research. He was previously the Vice President of Clinical Development and Medical Affairs at Altus Pharmaceuticals Inc. Dr. Attie also served as the Chief Medical Officer at Insmed Inc., where he was responsible for obtaining FDA approval of an IGF-1-related product. Prior to that, Dr. Attie worked for 12 years at Genentech, where he was respon-sible for several phase I-IV studies and participated in 9 FDA submissions for growth hormone. Dr. Attie was Assistant Clinical Professor of Pediatrics at the University of California San Francisco Medical Center, is board-certified in Pediatrics and Pediatric Endocrinology, and has over 40 publications in peer-reviewed journals. Dr. Attie received a BA in Music from the University of Michigan, Ann Arbor and an MD from New York University Medical Center.
June 3, 2014Harvard Club of Boston
Biographies 11
Abigail BarrowFounding Director, Massachusetts Technology Transfer Center and Conference Co-Chair
Abigail Barrow is the Founding Director of the Massachusetts Technology Transfer Center (MTTC). The MTTC is state funded and supports technology transfer activities from public and private research institutions to companies in Massachusetts. The Center works with technology transfer offices at all research institu-tions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth. Prior to joining the MTTC, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the Jacobs School of Engineering. Dr. Bar-row worked in a variety of roles at UCSD CONNECT from 1990 to 2001. CONNECT’s programs focused on supporting early stage high-tech and biotech companies and in particular helping them raise funding from venture capitalists and corporate partners. Dr. Barrow has also worked with other countries where the CONNECT program has been successfully replicated. Dr. Barrow is on the board of the National Collegiate Inventors and Innovators Alliance (NCIIA), on the scientific advisory board of Norway’s Simula Research Laboratory, and an Xconomist for Xconomy.com.
Jeff BehrensPresident and CEO, Sialix, Inc.
Jeff is President and CEO of Sialix, Inc., a biotech company focused on developing therapeutic antibodies targeting glycan targets in cancer. Previously, Jeff served as Senior Director, Business Development and Operations at Edimer Pharmaceuticals and also worked at Alnylam and Biogen Idec. In 2003 Jeff sold his healthcare IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup. Telluride was an information technology managed services provider (MSP) founded in 1995. Jeff has a Lecturer ap-pointment and currently teaches in the HST PhD program at MIT and Harvard Medical School. Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He lives in Newton, MA.
Carl BerkePartner, Partners HealthCare Innovation Fund
Carl is a Partner at the Partners HealthCare Innovation Fund in Boston, investing in new biomedical tech-nologies emerging from Massachusetts General Hospital and Brigham & Women’s Hospital. His career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets - he is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a consulting firm, focusing on the management of innovation and growth strategy. He has been an active private equity investor as a mem-ber of Angel Healthcare Investors LLC and is a founding director of Mass Medical Angels. He has served on the boards of Quosa (research literature management software), Kasalis (robotics), Annovation (anesthetic agents), Combinent (women’s health), Sebacia (acne treatment), InfoBionic (cardiac monitoring) and the Sudanese Education Fund (philanthropy). Carl holds an AB degree from Cornell University and received his Ph.D. in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technol-ogy.
7th AnnualMassachusetts Life Sciences Innovation Day
12 Biographies
Scott BillerChief Scientific Officer, Agios Pharmaceuticals
Scott Biller joined Agios Pharmaceuticals as Chief Scientific Officer in September of 2010. Agios, a biotech in Cambridge, Massachusetts, is focused on the discovery of novel antitumor therapeutics that capitalize on the metabolic dysregulation of cancer cells, as well as the discovery of therapies for rare genetic metabolic disorders. Scott has nearly 30 years of drug discovery and development experience. Previous to Agios, he was Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research (NIBR). In this capacity, he was responsible for the world-wide discovery chemistry functions at NIBR, including medicinal, combinatorial and computational chemistry, as well as the research metabolism and pharmacokinetics function. Scott joined NIBR in 2003 and played a key role in building the new research organization in Cambridge, Massachusetts, as well as reinventing the Novartis culture of innovation glob-ally. Through his leadership together with that of other NIBR scientists, the new Cambridge site was able to progress from the research phase to their first positive human proof-of-concept within 4 years. Scott established the first research metabolism and pharmacokinetics function at Novartis in 2005, which is now a robust global effort across four sites. In 2007, he proposed and established a new strategy for externaliza-tion of drug discovery programs that are outside of current disease area strategy. In a short period of time, this approach led to multiple clinical candidates currently in the Novartis development pipeline. Scott held the position of Vice President, Pharmaceutical Candidate Optimization at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute. Scott’s work focused on the identification of superior drug candidates by optimization of the physicochemical, ADME and safety attributes of molecules in parallel with efficacy. This strategy significantly increased the success rates at BMS from drug candidate nomination to late develop-ment. Prior to this position, he was the Executive Director of Drug Discovery Chemistry for the BMS research site in Lawrenceville, New Jersey. He was responsible for overseeing chemistry for oncology, immunology, inflammation and pulmonary diseases. Among his other key senior positions at BMS, Scott was the Execu-tive Director of Metabolic Diseases Chemistry, with responsibility for medicinal chemistry programs in hy-percholesterolemia and atherosclerosis, diabetes, obesity, osteoporosis and endocrine dysfunctions of the aging population. Under his leadership, the Metabolic Diseases Area delivered multiple clinical candidates, including three marketed drugs: the ,DPP4 inhibitor OnglyzaTM (saxigliptin) for Type 2 diabetes, the SGLT2 inhibitor ForxigaTM(dapagliflozin) for Type 2 diabetes and the MTP inhibitor JuxtapidTM (lomitapide) for fa-milial hypercholesterolemia. The latter two molecules are first in class in their category. Scott gained his SB degree at the Massachusetts Institute of Technology in 1976 where he did undergraduate research with K. Barry Sharpless. He completed his PhD in Organic Chemistry in 1982 at the California Institute of Technology under the tutelage of David Evans, and held an NIH.
Kevin BittermanCEO, Editas Medicine
Kevin is a Partner at Polaris Partners and is acting CEO of Editas Medicine. He joined Polaris in 2004 and fo-cuses on investments in healthcare. Prior to joining Polaris, Kevin completed his PhD in genetics at Harvard Medical School. He is a cofounder of Genocea Biosciences (NASDAQ: GNCA) and Sirtris Pharmaceuticals (GSK) and was the founding CEO at Visterra Inc. Kevin currently represents Polaris as a Director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical, and Vets First Choice.
June 3, 2014Harvard Club of Boston
Biographies 13
Nancy BriefsCEO and Co-Founder, InfoBionic
Ms. Briefs’ background includes 30+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm shifting technologies with five (5) prior med-tech startups. Having raised over $200M in venture capital and four successful liquidity events (including an IPO with Goldman Sachs) she has proven the ability to lead teams from concept thru commercialization and value creation. She was awarded: with the Ernst & Young (EOY) New England Entrepreneur of the Year Award for Emerging Companies in 2003; received the “Spirit Award” in 2009 from NH Biotech Council and in 2010 was honored with a “Leadership & Inspiration: Award from WEST(Women Entrepreneurs in Science and Technology). She currently serves on the Boards of: MDMA (Medical Device and Manufacturers Association),CardiAQ Valve Technologies, and InfoBionic. An entrepreneur inventor she is listed on seven issued and two pending US patents. Nancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. A notable and inspiring public speaker, Ms. Briefs has spoken at the MIT Enterprise Forum, ADVAMED, Harvard Medi-cal School, Tuck School at Dartmouth College, NH Women’s Leadership Conference, Smith College, WEST, MassMEDIC, MIT Sloan School, Venture One, MDMA, MedTech Insight, OneMedForum and other numer-ous industry events.
Richard BurttManaging Director, Value Added Strategies, LLC
As Managing Director of Value Added Strategies, LLC (VAS), Mr. Burtt advises senior management of med tech and medical device businesses in the commercialization stage and has successfully raised over $55 million in angel and venture capital in his role as CEO and as a BOD member. Currently Mr. Burtt serves as Chairman of Grove Instruments, Inc. and Advanced Aesthetics Technologies, Inc. Earlier in his career, Mr. Burtt was Executive Vice President of Andover Medical Industries (May 1978-June 1983), a private cardio-vascular technology company acquired by Medtronic. Following that acquisition, Mr. Burtt developed exper-tise in corporate development, acquisitions, and international marketing as a Vice President for Medtronic (1983-1989). In summary, he co-founded or led five businesses (Andover Medical, NEMF, IDVehicle, DTAC, and Origin Data) to acquisition exits. Mr. Burtt has successfully raised over $55 million in angel and venture capital in his role as CEO and as a BOD member achieving consistent shareholder value. Mr. Burtt has earned the Advanced Professional Director Certification for Public Companies from the American College of Corporate Directors (2011) and has over 30 years’ experience as an independent Board member and cur-rently serves on the Board of Directors for Grove Instruments, Inc., Advanced Aesthetic Technologies, Inc., Paragonix Technologies, Inc., WiFiMed, Inc., and Friends of Charlestown Navy Yard, a non-profit. Mr. Burtt holds a MS in Chemical Engineering from the University of Massachusetts (Lowell).
Ashok ChanderCEO, Cellanyx Diagnostics
Ashok Chander, CEO of Cellanyx Diagnostics developed Cellanyx’s core technology during a career in academic research spanning topics from multidrug resistance to matrix-biology. He is a Fellow of Startup Leadership Boston and holds a Ph.D. from Columbia University and a S.B. in biology from MIT. Ashok en-
7th AnnualMassachusetts Life Sciences Innovation Day
14 Biographies
joys collaborating with engineers, scientists and executives towards advancing our understanding of bio-logical processes, discovery, developing clinically relevant technologies, and creating sustainable clinical & therapeutic value.Ashok is currently engaged in the development of an in vitro cancer prognostic technology and cell-based assay platform to screen for novel compounds that inhibit cancer growth and metastasis. Grounded in a strong interest in mammalian biological research, Ashok is passionate about translating basic scientific discoveries into therapeutic gains. Ashok began his scientific training at NIH, continuing at MIT and Columbia University while being advised by two Nobel Laureates along the way. In addition to oncology re-search, Ashok has been engaged in research relevant to cystic fibrosis, synaptic plasticity, and Alzheimer’s. Ashok has experience spanning academic research, entrepreneurship, and business in life sciences, oncol-ogy, medical device, healthcare, information technology and diagnostic industries. Ashok has been engaged in oncology research since 1996.
Robert CopelandScientist, Author, Entrepreneur
Robert A. Copeland, Ph.D. is Executive Vice President and Chief Scientific Officer at Epizyme, Inc. He joined Epizyme in September 2008, from GlaxoSmithKline, where he was Vice President of Cancer Biology, Oncol-ogy Center of Excellence in Drug Discovery. Dr. Copeland has also served on a number of advisory boards, committees and editorial boards in industry, academia, professional societies and professional journals, including: Adjunct Professor and Fellow of the University of Pennsylvania School of Medicine; American Chemical Society Committee for Professional Training; Governance Council of the American Society for Biochemistry & Molecular Biology; Editorial Board of the Journal of Biological Chemistry; and Editorial Board of Molecular Cancer Therapeutics. Before joining GSK he held scientific staff positions at Merck Research Laboratories, DuPont-Merck and Bristol-Myers Squibb and a faculty position at the University of Chicago, Pritzker School of Medicine. Dr. Copeland received his B.S. in chemistry from Seton Hall University, his doc-torate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. His research interest is in elucidating the determinants of drug recogni-tion by their biological targets, and the use of this information in the discovery and design of new medicines. A common theme throughout his research has been the role of protein dynamics in drug-target interactions. In 2005-2006 Dr. Copeland formulated the concept of drug-target residence time, a novel, alternative ap-proach to drug optimization that has been widely adopted throughout the biotechnology and pharmaceutical industries. He has contributed to drug discovery and development efforts across a wide range of therapeutic areas leading to 17 drug candidates entering human clinical trials. These include the cancer drugs Tafinlar (Dabrafenib), Foretinib and Mekinist (Trametinib) and the antibiotic Altabax (Retapamulin). Dr. Copeland has contributed more than 190 publications to the scientific literature, holds 9 issued U. S. patents and has authored 5 books in the areas of protein science and enzymology.
John DelyaniExecutive Director, Business Development and Licensing, Merck, Boston Innovation Hub
Dr. Delyani has approximately 20 years of experience in the pharmaceutical and biotechnology industry and has negotiated over 30 partnerships and licenses. Dr. Delyani currently serves in the business development leadership at the Merck Boston Innovation Hub. Prior to Merck, Dr. Delyani spent 8 years at the Novartis Institutes of BioMedical Research (NIBR) as the Head, Therapeutic and Technologies for Strategic Alliances (SA) where he led a team responsible for identifying and evaluating innovative partnering opportunities across all disease and technology platform areas, served as a SA leadership team member, and led selected transactions. Prior to joining NIBR, Dr. Delyani was Senior Director of Business Development at Kalypsys, a
June 3, 2014Harvard Club of Boston
Biographies 15
biotechnology company focusing on metabolic, inflammation, and oncology small molecule therapeutics and VP, Business Development for Quark Biotech. Dr. Delyani began his career at Searle/Pharmacia where he held positions of increasing levels of responsibility in R&D and business development, including Associate Director, Cardiovascular Research and Director of Technology Acquisitions. He holds a Ph.D. in cardiovas-cular physiology from the State University of New York at Buffalo and a MBA from Maryville University in St. Louis.
Nathan has over 22 years of experience in the healthcare field. He specializes in business strategy, or-ganizational design, business model evolution, lifecycle planning, market entry and geographic expansion strategies, internal venture development, spin-outs, public-private venturing, and acquisition, licensing, and alliance candidate valuation. Nathan’s technology platform experience includes small molecules, biotechnol-ogy, diagnostics, and medical devices. His clients have included executive and technology teams at global life science firms, emerging mid-size specialists, banks, hedge funds, and start-ups. Nathan has spoken at conferences and authored several articles on a wide variety of healthcare topics. He has also served as a start-up board member.
Eric EvansMass Medical Angels
Eric J. Evans is an active member of the early-stage investor community in Boston. He sits on the Execu-tive Committee of Mass Medical Angels and on the Screening Committee of Launchpad Ventures. Since many early-stage deals are now syndicated, he also maintains relationships with Hub Angels, Boston Harbor Angels and Cherrystone, among others. He has served as CEO for several biomedical companies, includ-ing Targeted Cell Therapies, Abazyme, Lumos Catheter Systems, Mulleris Therapeutics and Follica Biosci-ences. He began his career at Procter & Gamble and at the Boston Consulting Group. Mr. Evans holds a master’s degree in finance and public policy from the Wharton School at the University of Pennsylvania, and a bachelor’s degree in nuclear physics from Brown University.
Ronald FarquharSenior Vice President, Discovery and Pharmaceutical Sciences, Cubist Pharmaceutical
Dr. Ronald Farquhar has served as Cubist’s Senior Vice President of Discovery and Pharmaceutical Sci-ences since November 2011. Previously, since January 2009 he was Vice President, Discovery Biology. Be-fore joining Cubist, from July 2005 to October 2008, he was Divisional Vice President and General Manager, Pre-clinical Services, Charles River Laboratories, Inc. Earlier, from 2003 to 2005, he was Vice President, Research and Pre-clinical Development at Activbiotics, Inc. From 1998 to 2003 Dr. Farquhar was senior program director for infectious diseases at Millennium Pharmaceuticals, and in 2000 he became the senior program director for the Millennium-Bayer alliance. In 1989, Dr. Farquhar joined Pfizer Central Research in Sandwich, England, and over the following nine years he held leadership roles in infectious disease drug discovery as well as technology development. Dr. Farquhar received a bachelor’s and D. Phil. degree in mi-crobiology in the United Kingdom from Edinburgh University and Oxford University, respectively.
7th AnnualMassachusetts Life Sciences Innovation Day
16 Biographies
Meredith FischerDirector, Partner Investments, Boston Family Office
Meredith Fisher currently serves as a Director, Partner Investments for the family office of a Boston area hedge fund. Her previous roles include serving as Head of Business Development at Ginkgo BioWorks, a synthetic biology company and as Senior Director of Technology and Business Development at Enlight Bio-sciences, a Boston-based venture creation company established in partnership with major pharmaceutical companies. Meredith completed her MBA at the MIT Sloan School of Management and her PhD at Harvard University in molecular microbiology. She received her undergraduate degree from Mount Holyoke College.
Johannes FruehaufFounder and President, Cambridge BioLabs & Executive Director, LabCentral
Dr. Fruehauf is a serial entrepreneur and scientist with a track record in building successful biotechnology companies. He is the owner of Cambridge BioLabs, an early-stage contract research organization in Kendall Square. He is also the Founder & President of LabCentral, a large non-profit shared laboratory for startup life science companies. Before starting ViThera, he was a co-founder of Cequent Pharmaceuticals (sold to Marina Biotech, Nasdaq MRNA) and served as Head of R&D. He serves as a Board Director or advisor to a number of biotechnology companies. He completed his post-doc with Dr. Chiang Li at the Beth Israel Deaconess Medical Center and invented the bacterial RNAi technology transkingdom RNA interference, the only RNAi therapeutic targeting the gastrointestinal tract. Dr. Fruehauf is the author of over 20 peer reviewed publications and is a named inventor on 14 patents related to RNA interference and bacterial therapeutics.
Serban GeorgescuDirector, Business and Clinical Development, InfoBionic
Dr. Georgescu is a physician with over 19 years of Cardiology, research and business experience. His clini-cal background included working in cardiac catheterization and research labs at the University of Tokyo and Tufts Medical Center in Boston. His research including molecular and cellular biology, genetics, and animal and human studies, led to 11 peer-reviewed original articles and one book chapter. Dr. Georgescu is passion-ate about start-ups and helping new technologies come to life resulting in his leaving the research labs for his current role. At InfoBionic he is responsible for identifying and reviewing new complimentary technologies and for clinical oversight in product development. In addition, Dr. Georgescu continues to lead due diligence efforts at Massachusetts Medical Angels (MA2), a life sciences-focused angel investment group. Multilingual, with great international experience having lived and worked in Romania, Japan and USA, he is comfortable in any global environment. Dr. Georgescu earned his M.D. with honors from the Carol Davila University of Medicine and Pharmacy in Romania, and his MBA cum laude from Babson College.
June 3, 2014Harvard Club of Boston
Biographies 17
Lana GladsteinPartner, Pepper Hamilton LLP
Lana A. Gladstein is a partner with Pepper Hamilton LLP, resident in the Boston office. Ms. Gladstein’s prac-tice is devoted to intellectual property litigation, licensing, and the Food and Drug Administration’s laws and regulations pertinent to drugs and medical devices. Ms. Gladstein is a frequent speaker on legislative and FDA developments in the areas of biologics and medical devices.Ms. Gladstein received her undergraduate degree from Brandeis University, with a concentration in biology (B.A., cum laude, 1997). She received her law degree from Northeastern University School of Law (J.D. 2000), where she was founder and president of the Intellectual Property Society. During law school, she served as a law clerk to the Honorable Margaret H. Marshall, Chief Justice of the Supreme Judicial Court of Massachusetts. Ms. Gladstein is admitted to practice in Massachusetts, as well as before the U.S. Patent and Trademark Office, the U.S. District Court for the District of Massachusetts, and the U.S. Courts of Appeals for the First and Federal Circuits. She is a member of the Boston Bar Association, the American Intellectual Property Law Association and the Licensing Executives Society.
Laura HalesCBO and Co-Founder, Extend Biosciences Inc.
Laura M. Hales is a co-founder and Chief Business Officer of Extend Biosciences Inc., an emerging biotech-nology company that is developing a novel drug delivery platform technology that improves the pharmacoki-netic properties of peptides and proteins. The company has several internal programs under development, as well as multiple partnerships with academia, small biotech and large pharma companies. At Extend Bio-sciences, Dr. Hales manages all of the outsourcing, operational and business development activities for the company. She has also been instrumental in obtaining the $2M+ in non-dilutive SBIR funding the company received in 2013-14 from NIH, NSF and the Department of Defense. Dr. Hales initiated operations at the company and led early efforts to complete proof-of-concept studies while incubating the company virtually as a finalist in MassChallenge’s inaugural accelerator program (2010). Prior to founding Extend Biosciences, Dr. Hales was one of the first five employees at Purdue Pharma’s research facility in Princeton, NJ, where she led multiple project teams developing antibody-based therapies for cancer. Following that, she was the second employee at the venture-backed startup company Neotropix, Inc. where she was part of a 6-person team that brought an oncolytic virus into the clinic in just 13 months. During this part of her career, she built and managed multidisciplinary preclinical research teams, managed external collaborations, conducted due diligence activities, co-authored a successful IND application, and gained in-depth knowledge of the techno-logical and developmental aspects of biologics drug discovery. Dr. Hales is also the Founder and Principal at The Isis Group, a scientific communications and consulting company where her primary focus is to assist life science entrepreneurs in new business formation and non-dilutive funding efforts. In addition, she serves on NIH peer-review panels for SBIR/STTR grants, and is on the editorial board of Life Science Leader maga-zine. Dr. Hales received her Ph.D. at the University of Illinois at Urbana-Champaign and was a postdoctoral fellow at Columbia University. She blogs about SBIR grant writing at www.isis-editing.com/blog. You can fol-low her tweets on non-dilutive funding, the life science industry and the startup scene in Boston/Cambridge @extendbio.
7th AnnualMassachusetts Life Sciences Innovation Day
18 Biographies
John HallinanChief Business Officer, MassBio
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs. John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background en-compasses venture financings, corporate development, technology licensing, and mergers and acquisitions. Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio-serving on the Economic Development Ad-visory Group and as co-chair of the Finance Committee & Entrepreneur’s University. Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding. John holds a BBA from St. Bonaventure University and is a certi-fied public accountant. He lives with his wife Denise in Marlborough, MA.
Laurie HalloranPresident & CEO, Halloran Consulting Group
Laurie founded Halloran Consulting Group in 1998. With over 25 years of experience in clinical affairs man-agement with contract research organizations and biotechnology companies, Laurie is recognized as an industry expert in improving organizational effectiveness, and has an extensive track record in accelerated/focused growth, realignment, and innovative organizational solutions. She is highly regarded as a results oriented leader with strong interpersonal skills, and the ability to create, evaluate, analyze, and implement defined plans and objectives to achieve organizational goals. As a cross-functional executive she has bal-anced experience in strategy, marketing and business development operations and administration. She is known for her work in complex organizational environments with conflicting objectives and a need to develop a broader system view, while effectively engaging constituents to achieve goals. Under her guidance and leadership Halloran has increased revenues by 25% per year and now serves an international client base in the biopharmaceutical, medical device and professional services sectors. Prior to founding Halloran Consult-ing Group, Laurie spent 16 years working within the life science industry, in both biopharma companies and service companies. She is an adjunct professor at Boston University Medical School, has been an instruc-tor at George Washington University, and Harvard, and lectures at the Tufts Center for Drug Development Post-Graduate program. In 2010, she was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice and in 2009 was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals. Laurie earned a B.S. in Nursing from Russell Sage Col-lege and an M.S. in Management from Leslie University. She is also a Prosci certified change management consultant.
June 3, 2014Harvard Club of Boston
Biographies 19
Emily HickeyCorporate VP, Charles River Laboratories
Emily Hickey is Corporate Vice President for Discovery Research Services. She is an experienced drug discovery executive with a proven track record for establishing and leading a successful global discovery business. Her career spans from target discovery through preclinical development in a global pharmaceutical organization for both human and animal health. Emily was the Executive Director of In Vivo Pharmacology at Merck Research Labs, leading the development and implementation of the externalization strategy for in vivo studies.
Mark LevinFounder,Third Rock Ventures, LLC
Mark Levin is an industry leader with more than 38 years of experience, including 31 years building and operating leading biotech companies. Mark co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of our portfolio companies, as well as actively identifying and evaluating new investments. He also assumes active leadership roles in our portfolio companies, functioning as CEO through the first 12-18 months post launch. Mark was co-founder of Mayfield Fund’s life sciences effort where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Mil-lennium Pharmaceuticals. Mark served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, Mark was an engineer and project leader at Lilly and Genentech. Mark holds an MS in Chemical and Biochemical Engineering from Washington University. He is a member of the National Academy of Engineer-ing, the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, MA. Cur-rent Roles: Board Member of Blueprint Medicines; Board Member of DC Devices; Board Member of Eleven Biotherapeutics, former interim CEO; Board Member of Foundation Medicine; Board Member of NinePoint Medical, former interim CEO; Interim CEO of Voyager Therapeutics; Board Member of Warp Drive.
Steven LondonPartner, Pepper Hamilton LLP
Steven R. London is a partner in the Corporate and Securities Practice Group of Pepper Hamilton LLP, resi-dent in the Boston office. Mr. London concentrates his practice on corporate finance, securities and general corporate matters, and focuses on emerging growth companies and middle-market businesses. For the past 30 years, Mr. London’s activities have included public and private equity and debt offerings, venture capital financings, mergers and acquisitions, and Securities and Exchange Commission compliance matters. He represents, as general and special counsel, publicly traded corporations (stock exchange and Nasdaq listed), emerging high-technology growth companies and entrepreneurs in the initial start-up and develop-ment stages of business. He also represents foreign companies entering the U.S. market. Mr. London has extensive experience in negotiating licensing, manufacturing, marketing and distribution agreements, joint ventures and strategic alliances.
7th AnnualMassachusetts Life Sciences Innovation Day
Salvatore Mascia is the Founder & CEO of CONTINUUS Pharmaceuticals. He was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the first end-to-end continuous manufacturing process for pharmaceuticals. At the end of the project, he was presented with the “Leadership Award” that recognized his leadership role at the Center. Salvatore has gained experience in strategic management and fund raising in addition to leadership skills via various roles of responsibility within the entrepreneurial ecosystem. Among those, he co-founded “Professional Italians in Boston” in 2009, and served as President of the “Cambridge University Technology and Enter-prise Club” in 2006/07. He also ran a pharmacy business for 2 years. Salvatore completed a post-doc at MIT in Chemical Engineering and holds a PhD in Chemical Engineering from the University of Cambridge, UK and a BS and MS in Pharmacy (summa cum laude) from University of Perugia, Italy.
Angus McQuilkenVice President for Communications & Marketing, Massachusetts Life Science Center
Angus McQuilken joined the MLSC in 2008, and he currently serves as Vice President for Communications & Marketing. In this capacity he oversees media relations, electronic communications, event coordination, trade shows and other marketing activities. Prior to his work at the MLSC, Angus served as Vice President for Public Affairs for Planned Parenthood League of Massachusetts, as Deputy Communications Direc-tor for the Democratic National Convention Committee, and as Chief of Staff for State Senator Cheryl Jacques. Angus holds a Bachelor’s in political science from the University of Massachusetts at Amherst. In 2008 he received the Distinguished Citizen Award from the Massachusetts chapter of the American Society for Public Administration. He enjoys basketball, long-distance bicycling and politics.
Mark NamchukSenior Vice President of Research for North America, Vertex Pharmaceuticals
Dr. Namchuk received his BSc in Chemistry with Honors from the University of Alberta in 1988 and his Ph.D. in Bioorganic Chemistry from the University of British Columbia in 1993. Upon completion of his graduate work, Dr. Namchuk was an HFSP Post Doctoral Fellow at UCSF. In 1996 he accepted a position with Cubist Pharmaceuticals as the head of the Enzymology group. In 1998, he joined Vertex Pharmaceu-ticals and has held a number of positions with the company. In 1999, he took on responsibility for the High Throughput Screening group. After leading drug discovery teams in infectious disease and oncology, he was promoted in 2002 to Worldwide Head of preclinical research for the Vertex/Novartis Kinase Program, and in 2003 took responsibility for all aspects of the alliance across R and D. In 2005, Dr. Namchuk was made Vice President of Research for Vertex’s Cambridge site. In 2011 he was promoted to his current posi-tion as senior Vice President of Research for North America. In this position he manages 350 scientists in 4 sites working in all areas of pharmaceutical research including Medicinal Chemistry, Structural Biology, Biochemistry, Cell Biology and Pharmacology and oversees projects in areas of Infectious Disease, Oncol-ogy, IMID, Neurology and Cystic Fibrosis.
June 3, 2014Harvard Club of Boston
Biographies 21
Michal PremingerExecutive Director, Harvard University Office of Technology Development
Dr. Michal Preminger is currently Executive Director at the Harvard University Office of Technology Develop-ment, overseeing the Harvard Medical School site. Prior to joining Harvard, she held a number of business development and technology development positions at Compugen (NASDAQ:CGEN), most recently as Vice President of Protein Therapeutics, responsible for the business management of the company’s emerging drug discovery pipeline. Previously, Michal held several marketing and business development in the hi-tech industry, among others for Lucent Technologies, and co-founded a biotechnology startup. Additionally, Dr. Preminger has served, in the past and present, as a Member of the Board of Directors in multiple companies, including among other Alma Lasers, BioArray Therapeutics, and Elminda and as the member of the Scientific Advisory Board of Prize4Life, a not-for-profit organization focused on the promotion of research in the area of ALS. Dr. Preminger holds a Ph.D. and an M.Sc in Biological Sciences from the Weizmann Institute of Sci-ence in Israel; a bachelor degree in Medical Sciences from the Hadassah Medical School, Hebrew Univer-sity, Jerusalem; and an MBA from INSEAD in France.
Brock ReeveExecutive Director, Harvard Stem Cell Institute
Brock Reeve is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Direc-tors, he has overall responsibility for the operations and strategy of the Institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases. HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of the Executive Committee, HSCI invests in scientific research and its faculty has grown to include over 300 Principal and Affiliated members. The Institute is engaged with several leading pharmaceutical companies and foundations in joint research projects and its faculty have founded several stem cell-related startup companies and serve on leading Scientific Advisory Boards. Brock came to this role from the commercial sector with extensive experience in both management consulting and opera-tions for technology-based companies, with a focus on life sciences. Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.
Ifat Rubin-BejeranoCo-Founder and CSO, ImmuneXcite
Dr. Ifat Rubin-Bejerano is a Co-Founder of ImmuneXcite and serves as its Chief Scientific Officer. She con-ducted her postdoctoral studies at the Whitehead Institute of MIT with Prof. Gerald R. Fink, where she was interested in the host-pathogen interaction of fungi with immune cells. Her research led to the identification of a fungal carbohydrate that recruits and activates neutrophils, which she then conjugated to cancer-specific antibodies to direct neutrophils to tumors. Ifat has been instrumental in translating the basic science into a commercial platform technology and has been leading the R&D efforts at ImmuneXcite. Dr. Rubin-Bejerano holds a Ph.D. and a B.Sc. magna cum laude from the Technion-Israel Institute of Technology.
7th AnnualMassachusetts Life Sciences Innovation Day
22 Biographies
Aaron SandoskiCo-founder and Managing Director, Norwich Ventures
Aaron is a specialized venture capital firm focused on early-stage MedTech. Aaron currently serves on the Board of Directors for Daktari Diagnostics, Pelvalon, Podimetrics, and Vaxess Technologies. Previously, he served on the board of Intelligent Bio-systems (acquired by Qiagen) and was actively involved in Rhythmia Medical (acquired by Boston Scientific). Prior to co-founding Norwich Ventures, Aaron began his career as a consultant at McKinsey & Company and DEKA R&D. Aaron serves as a board member of MedTech IGNITE, a MassMEDIC initiative for early-stage medical device companies. Aaron earned an MBA from Harvard Busi-ness School and A.B.’s in Chemistry and Economics from Dartmouth College.
Kristin SchneemanDirector of Programs, FasterCures
Kristin Schneeman joined FasterCures in April 2005 as program director, with primary responsibility for its innovation portfolio of projects and activities, focused on best practices in the funding and conduct of medical research and innovative collaborations among players in the research enterprise. She brings to FasterCures 20 years’ experience in public policy, politics, academia, and the media. Schneeman served for three years as a senior adviser and policy director to a gubernatorial candidate in Massachusetts, as a policy aide to a U.S. Congressman, and for four years as the front-line manager and chief-of-staff for a senior adviser to Vice President Al Gore. At Harvard University’s Kennedy School of Government, she directed a research project - the top priority of the dean of the school - on future challenges facing governments, and at Harvard Business School she worked with a noted professor who specializes in analyzing and advising on complex negotiations in business, politics, and international relations. Schneeman began her career as a producer of documentary films on political and social issues, for which she was the recipient of an Emmy Award in 1990.
Juswinder SinghScientist and Entrepreneur
Juswinder Singh, Ph.D. is a scientist and entrepreneur. He founded Avila Therapeutics in 2007 and was the Chief Scientific Officer until its acquisition by Celgene in 2012. Dr. Singh is a computational chemist and structure-based small molecule drug designer, developing methods that have been successfully ap-plied in the discovery of multiple NCEs, several of which are now in clinical development. Prior to Avila, he led computational chemistry efforts at Biogen Idec, where he most recently served as Director of Structural Informatics, and he also pioneered the development of novel approaches in computational chemistry and cheminformatics at Parke-Davis. He has published more than sixty five papers in peer-reviewed journals one book and multiple patents. He was the Senior Editor of the journal, Chemical Biology and Drug Design until 2012. Dr. Singh received his PhD in rational drug design at the University of London followed by a post-doctoral fellowship at University College London.
June 3, 2014Harvard Club of Boston
Biographies 23
Avi SpierDirector of Strategic Alliances, Novartis Institutes of Biomedical Research (NIBR)
Avi is a Director of Strategic Alliances in NIBR, with responsibility for search and evaluation activities for the Cardiovascular and Metabolism (CVM), Global Discovery Chemistry (GDC), Center for Proteomic Chemistry (CPC) and GNF organizations. Prior to Novartis, Dr. Spier co-founded Allon Therapeutics, Inc. and led the neurodegenerative disease focused company as its President and CEO through two financing rounds and up to its entry onto the Toronto Stock Exchange.
David VerrillFounder&Managing Director, Hub Angel Investment Group, LLC & Chairman, Angel Capital Association
David’s professional career began as a research scientist at the Center for Blood Research in Boston focus-ing on the MHC of genetically engineered mice. After receiving his master’s degree from Sloan in 1987, he spent a decade at MIT raising capital from industry and facilitating technology transfer. David still holds a partial appointment at the MIT Sloan Center for Digital Business, and is helping Sloan develop a new Initia-tive on the Digital Economy. In 1996 he joined Xerox as Manager of International Sales and Business De-velopment for the Adaptive Products Division before it was sold. In 1998 David joined third party marketing firm Winchester International Group as Managing Director. In 2000 Winchester helped found the Hub Angels, a series of early stage investment funds in Boston. David sits on the Board of Content Raven and is Chair-man of the Angel Capital Association. David was educated at Bowdoin College and the MIT Sloan School of Management.
Todd ZionFounder, SmartCells, Inc.
Todd C. Zion, Ph.D. founded SmartCells, Inc. in 2003 to develop SmartInsulin, the first glucose-regulated, injectable formulation for treating diabetes. As SmartCells’ President and CEO, Todd was instrumental in raising $10M in equity financing from individual investors and $10M in grants to support research and clinical development. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments. Dr. Zion developed the SmartInsulin technology as part of his doctoral thesis work in Chemical Engineering at the Massachusetts Institute of Technology. Prior to enrolling at MIT, he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering. Dr. Zion now enjoys advising technology entrepreneurs through MIT’s Venture Mentoring Service. He also serves on a number of advisory boards including those of the Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering College Council.
7th AnnualMassachusetts Life Sciences Innovation Day
24 Biographies
June 3, 2014Harvard Club of Boston
Planning Committee 25
MALSI Day Planning Committee
Chair
Abi Barrow, Massachusetts Technology Transfer Center
Content
Richard Anders, MA Medical AngelsAbi Barrow, Massachusetts Technology Transfer Center
Carl Berke, Partners HealthcareRoger Frechette, New England PharmAssociates
Sergio Davila, Harvard Biotech ClubRicha Dixit, Harvard Biotech Club
Julia Goldberg, Massachusetts Technology Transfer CenterChenning Lu, Harvard Biotech Club
Mark Yore, Harvard Biotech Club
Reception
Ashleigh Allard, Safety Partners, Inc.Denise Aronson, Safety Partners, Inc.
Lauren Laidlaw, T1D Exchange
Team
Anu Ahuja, VolunteerSuzanne Grillo, MassBioEd Foundation
Gary Lavine, Waltham Consulting Kevin O’Sullivan, MA Biotech Incubator
Avi Spier, Novartis
26 Sponsors & Organizers
7th Annual Massachusetts Life Sciences Innovation Day
Sponsors & Organizers 27
June 3, 2014Harvard Club of Boston
Sponsors and OrganizersGold Sponsors....................................................................................................................................... 28
Massachusetts Life Sciences Center .......................................................................................................................28Pepper Hamilton LLP....................................................................................................................................................29
Organizers .............................................................................................................................................. 32Massachusetts Technology Transfer Center .........................................................................................................32Mass Medical Angels ...................................................................................................................................................33Harvard Biotechnology Club .....................................................................................................................................33MALSI .................................................................................................................................................................................34
In association with ............................................................................................................................. 35Boston Life Science Networking .............................................................................................................................35CIMIT ..................................................................................................................................................................................35Harvard Alumni Entrepreneurs ................................................................................................................................35Lemelson-MIT .................................................................................................................................................................35M2D2 ..................................................................................................................................................................................35MASS-AWIS .....................................................................................................................................................................35Massachusetts Biomedical Initiatives ....................................................................................................................35MassChallenge Inc. .......................................................................................................................................................35MassMedic .......................................................................................................................................................................35Massachusetts Technology Collaborative ...........................................................................................................35Massachusetts Technology Leadership Council .................................................................................................35NCIIA ..................................................................................................................................................................................35NEVCA ...............................................................................................................................................................................35North Shore InnoVentures ........................................................................................................................................35OPEN .................................................................................................................................................................................35Seeding Labs ...................................................................................................................................................................35The Bioscience Network .............................................................................................................................................35The Capital Network ....................................................................................................................................................35TiE ........................................................................................................................................................................................35WEST ..................................................................................................................................................................................35University of Massachusetts ......................................................................................................................................35
28 Sponsors & Organizers
7th Annual Massachusetts Life Sciences Innovation Day
Gold Sponsor
Sponsors & Organizers 29
June 3, 2014Harvard Club of Boston
Gold Sponsor
Ever get the feeling that your lawyers don’t understand what you do? They may know the law, but
science or your business? Not so much. You need a law firm steeped in life sciences, who will be your
ally at every step from the lab bench to the board room — from the molecule to the market. A law
firm with more than half a century of experience in helping scientists and their businesses succeed.
You need lawyers who know you and the science — Pepper Hamilton LLP.
Biologically
We are proud to support Massachusetts Life Sciences.
Berwyn | Boston | Detroit | Harrisburg | Los Angeles | New York | Orange CountyPhiladelphia | Pittsburgh | Princeton | Silicon Valley | Washington | Wilmington
www.pepperlaw.com
30 Sponsors & Organizers
7th Annual Massachusetts Life Sciences Innovation Day
Silver Sponsor
300 Technology Square, Eighth FloorCambridge, MA 02139
(617) 674-5100www.MassBio.org
The Massachusetts Biotechnology Council is an association of more than 620 biotechnology companies, universities, academic institutions and other organizations dedicated to advancing cutting edge research. We are the leading advocate for the Bay State’s world premier life sciences cluster. We drive innovation by convening the biotechnology community. We work to educate policy makers and the general public on the life-changing work biotech companies do every day. Our eff orts help infl uence public policy and advance the economic interests of individual companies as well as the sector as a whole.
Networking & Professional DevelopmentWe bring members together to discuss relevant business and scientifi c issues and share their experiences through members-only Forums and networking events. These gatherings allow our members to discuss and share their experiences, ideas and advice about the numerous issues and challenges that life sciences companies face every day. MassBio, through MassBioEd, also off ers workforce development courses and training programs for those looking to learn more about specifi c disciplines within the industry.
Access to Capital & Fostering InnovationWith our Innovation Services arm, MassBio is focused on matching our member companies with the resources they need to move cutting-edge therapies from the bench to the bedside. Programs like our Pharma Days series provide a venue for leaders from burgeoning biotech companies to hear about the vision of larger biotech and pharmaceutical companies, venture fi rms, and non-dilutive funding sources, and to make connections that may become successful collaborations or strategic partnerships. MassCONNECT links new entrepreneurs with seasoned biotechnology professionals to provide industry expertise, evaluation, and guidance as a means to help commercialize new ideas.
Purchasing PowerBy aggregating the purchasing power of the member companies within MassBio, the Purchasing Consortium allows members to have a strong presence in the marketplace and benefi t from discounts and top notch customer service. Current Purchasing Consortium contracts allow MassBio members to access savings in key cost centers, including laboratory supplies, offi ce supplies & furniture, shipping, hazardous & biomedical waste removal, packaged and bulk gases, instrument maintenance, travel and mobile communications support.
Public Policy & AdvocacyBiotechnology is a complex, highly regulated industry. At MassBio, we work to educate policy makers and the public about the specifi c needs of our companies as they push the boundaries of science to improve our lives. As the state’s leading advocate for our life sciences supercluster, we fi ght for public policy initiatives and tax incentives in Massachusetts that will enable biotechnology companies to do their best work. At the same time, we maintain an active presence in Washington to help guide federal legislation.
Economic Development & Industry DataMassBio provides expert advice and guidance to help companies fi nd suitable locations and resources as they move to and grow in the Bay State. With initiatives like the BioReady® Communities Campaign, which rates a municipality’s zoning practices and infrastructure capacity for biotech development, we make Massachusetts a better place for your business. We also collect and disseminate current industry statistics, including employment and VC investment data.
MassBio Signature EventsWe bring together the various components of the life sciences supercluster through several compelling conferences and programs developed around the needs of our members. These events are opportunities for networking, educating and moving the industry forward. Annual events include the Policy Leadership Breakfast, the MassBio Annual Meeting and the MA CRO/CMO Symposium.
Sponsors & Organizers 31
June 3, 2014Harvard Club of Boston
Lathrop & Gage is proud
to support Massachusetts
Life Sciences Innovation Day
The choice of a lawyer is an important decision and should not be based solely upon advertisements. For more information, contact Giulio DeConti at (857) 300-4000.
CALIFORNIA | COLORADO | ILLINOIS | KANSAS MASSACHUSETTS | MISSOURI | NEW YORK
( 857 ) 30 0 - 40 0 0 | LATH ROPGAGE.COM
We salute this opportunity for the science and business communities to connect and collaborate.
She doesn’t know about clinical trials, histopathology or bacteriology. All she knows is that since she took that medicine, she feels well enough to play, and as far as we’re concerned, that’s all that matters. As a global provider of critical solutions for the advancement of drug discovery, we are a committed partner to accelerating the research and development of tomorrow’s therapeutics.
SHE OWES HER LIFE TO EARLY DETECTION, THE RIGHT PRESCRIPTION, AND A LITTLE WHITE MOUSE.
Conference Supporters
32 Sponsors & Organizers
7th Annual Massachusetts Life Sciences Innovation Day
The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Mas-sachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.
The Center supports the commercialization of research technologies through a variety of programs:
The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.
Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.
Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.
Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.
7th Annual Massachusetts Life Sciences Innovation Day
We are motivated to leverage what is truly unique about MA
“If I stand in the middle of Mass Ave Bridge, and walk 1 mile in either direction, I have everything I need to start a billion dollar life sciences company”
The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of public and private entities that work with emerging biotech and biomed companies. The prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who has a commercializable idea has easy and rapid access to the vast network of organizations and individuals who can help them realize their dreams. The Massachusetts Technology Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the Massachusetts Life Sciences Innovation Day.
The Organizing Committee thanks our Non-Profit Affiliates:
36 Sponsors & Organizers
7th Annual Massachusetts Life Sciences Innovation Day
June 3, 2014Harvard Club of Boston
Poster Presenters 37
Poster PresentersAdult Stem Cell Technology Center, LLC ..................................................................................... 40
James Sherley, Director
Advirna .................................................................................................................................................... 40Alexey Wolfson, CEO
Beth Israel Deaconess Medical Center ......................................................................................... 40Maria Kontaridis, Assistant Professor of Medicine, Department of Cardiology
Boston Children’s Hospital ............................................................................................................... 40Christine Coticchia, Postdoctoral Fellow, Vascular Biology Program
Boston Children’s Hospital ............................................................................................................... 41Jiang Yang, Ph.D., Vascular Biology Program
Boston Children’s Hospital ............................................................................................................... 41Andrej Jedinak, Post-doctoral fellow, Vascular Biology Program
Boston Children’s Hospital ............................................................................................................... 41Roopali Roy, Instructor, Vascular Biology Program
Brigham and Women’s Hospital/Volalytix ................................................................................... 41Sophia Koo, Assistant Professor of Medicine, Division of Infectious Diseases
Diagnostics For All ............................................................................................................................... 41Sahil Khullar, Research Associate
Forsyth Institute ................................................................................................................................... 42Karen Mullin, Chief General Counsel/Director of Technology Development
Forsyth Institute ................................................................................................................................... 42Sean Cotton, Senior Research Assistant/Technology Development Manager
Harvard Medical School .................................................................................................................... 42Jonathan Tang, PhD candidate, Dept. of Genetics
Harvard University .............................................................................................................................. 42Gerard Hilinski, Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology
intraThera/Tufts University ............................................................................................................... 42Qiaobing Xu, Assistant Professor, Biomedical Engineering
7th Annual Massachusetts Life Sciences Innovation Day
Massachusetts Institute of Technology ....................................................................................... 43Viktor Adalsteinsson, PhD Candidate, Koch Institute
Massachusetts Institute of Technology ....................................................................................... 43Manijeh Goldberg, Project Manager and the Senior Researcher
Massachusetts Institute of Technology ....................................................................................... 43James Loomis, Postdoctoral Associate, NanoEngineering Group
Northeastern University .................................................................................................................... 43Amir Farjadian, PhD Candidate, Bioengineering Department, College of Engineering
Northeastern University .................................................................................................................... 44Rajiv Kumar, Associate Research Scientist, Physics
Northeastern University .................................................................................................................... 44Srinivas Sridhar, Arts and Sciences Distinguished Professor of Physics
Riparian Pharmaceuticals ................................................................................................................. 44Will Adams, Chief Scientific Officer, President
StatVideo LLC ........................................................................................................................................ 44Al Kyle, Founder and President
TriBiotica, LLC (NSIV) ........................................................................................................................... 45Matthew Lawler, President
Tufts University ..................................................................................................................................... 45Karen Panetta, Professor, Department of Electrical and Computer Engineering
University of Massachusetts Medical School ............................................................................ 45Fatemeh Momen-Heravi, Postdoctoral Associate, Department of Medicine
Wyss Institute at Harvard University ............................................................................................. 45Xi Chen, Postdoctoral FellowEdward Doherty, Senior Staff Scientist
June 3, 2014Harvard Club of Boston
Poster Presenters 39
Wyss Institute at Harvard University ............................................................................................. 46Jonathan Kotula, Postdoctoral Fellow
Wyss Institute at Harvard University ............................................................................................. 46Thomas Valentin, Research Technician
7th Annual Massachusetts Life Sciences Innovation Day
40
Adult Stem Cell Technology Center, LLCPresented by: James Sherley, [email protected] Poster Title: A Computer Simulation Technology for Pre-clinical Identification of Drug Can-didates Toxic to Human Tissue Stem Cells
Beth Israel Deaconess Medical CenterPresented by: Maria Kontaridis, Assistant Professor of Medicine, Department of [email protected] Poster Title: Novel small molecule inhibitor for treatment of lupus
Boston Children’s HospitalPresented by:Christine Coticchia, Postdoctoral Fellow, Vascular Biology [email protected] Poster Title: Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer even among women who have normal CA125 levels
June 3, 2014Harvard Club of Boston
Poster Presenters 41
Boston Children’s HospitalPresented by: Jiang Yang, Ph.D., Vascular Biology [email protected] Poster Title: Neutrophil gelatinase-associated lipocalin (NGAL, lipocalin 2) induces the epi-thelial to mesenchymal transition (EMT) and promotes breast cancer invasion
Boston Children’s HospitalPresented by: Andrej Jedinak, Post-doctoral fellow, Vascular Biology [email protected] Title: Discovery and validation of non-invasive biomarkers for benign prostate hy-perplasia and prostate cancer
Boston Children’s HospitalPresented by: Roopali Roy, Instructor, Vascular Biology [email protected] Poster Title: Evaluation of Urinary MMPs and TIMPs as Potential Biomarkers for Pancreatic Cancer
Brigham and Women’s Hospital/VolalytixPresented by: Sophia Koo, Assistant Professor of Medicine, Division of Infectious [email protected] Title: Breathalyzer Platform for the Microbial Diagnosis of Pneumonia
Diagnostics For AllPresented by: Sahil Khullar, Research [email protected] Poster Title: Low -cost, point-of-care microfluidic diagnostic device for improving the pro-ductivity of dairy farmers in Sub-Saharan Africa
7th Annual Massachusetts Life Sciences Innovation Day
42
Forsyth InstitutePresented by:Karen Mullin, Chief General Counsel/Director of Technology [email protected] Poster Title: A Handheld Device for Delivering Photodynamic Therapy
Forsyth InstitutePresented by: Sean Cotton, Senior Research Assistant/Technology Development [email protected] Title: Tissue Regeneration Using Lipoxins and Resolvins
Harvard Medical SchoolPresented by: Jonathan Tang, PhD candidate, Dept. of [email protected] Title: A Nanobody-Based System Using Fluorescent Proteins as Scaffolds for Cell-Specific Gene Manipulation
intraThera/Tufts UniversityPresented by: Qiaobing Xu, Assistant Professor, Biomedical [email protected] Poster Title: intraThera: Revolutionizing protein-based drug delivery for oncology
June 3, 2014Harvard Club of Boston
Poster Presenters 43
Lumen Biomics, IncPresented by: Venky Soundararajan, Co-Founder & Chief Technology [email protected] Title: Structure-guided Precision Medicine in the Cloud- A New Era for Clinical Oncology
Massachusetts Institute of TechnologyPresented by: Viktor Adalsteinsson, PhD Candidate, Koch [email protected] Poster Title: Whole exome sequencing of circulating tumor cells provides a window into metastatic cancer
Massachusetts Institute of TechnologyPresented by: Manijeh Goldberg, Project Manager and the Senior [email protected] Poster Title: Safer Chemotherapy for Oral Cancer
Massachusetts Institute of TechnologyPresented by: James Loomis, Postdoctoral Associate, NanoEngineering [email protected] Title: Continuous Fabrication Platform for Highly Aligned Polymer Films (HAPFs): A Candidate Material for Therapeutic Hypothermia Applications
Northeastern UniversityPresented by: Amir Farjadian, PhD Candidate, Bioengineering Department, College of [email protected] Title: Interactive Cyclist Accident Prevention System (iCAPS)
7th Annual Massachusetts Life Sciences Innovation Day
44
Northeastern UniversityPresented by:Rajiv Kumar, Associate Research Scientist, [email protected] Poster Title: Implantable Nanoplatforms for Chemo-Radiation Therapy ‘INCeRT’ in On-cology
Northeastern UniversityPresented by:Srinivas Sridhar, Arts and Sciences Distinguished Professor of [email protected] Title: Electric Field Encephalography: Next Generation Neuromonitoring
Q-state Biosciences, IncPresented by: Graham Dempsey, Senior [email protected] Title: All Optical Electrophysiology For Disease Modelling and Compound Testing
Riparian PharmaceuticalsPresented by: Will Adams, Chief Scientific Officer, [email protected] Title:Discovering Novel Therapeutics to Reduce Vascular Inflammation
StatVideo LLCPresented by:Al Kyle, Founder and [email protected] Title: Real-time Review of video streamed medical images over the WEB
June 3, 2014Harvard Club of Boston
Poster Presenters 45
TriBiotica, LLC (NSIV)Presented by:Matthew Lawler, [email protected] Title: Templated Assembly of a novel antigen to allow T-cell recognition of tumor cells
Tufts UniversityPresented by:Karen Panetta, Professor, Department of Electrical and Computer Engineering
[email protected] Title: Novel Methods to Measure, Score and Rank the Quality of Biomedical Im-ages
University of Massachusetts Medical School Presented by: Fatemeh Momen-Heravi, Postdoctoral Associate, Department of Medicine [email protected] Title: Exosome-mediated delivery of RNA interference and miRNA mimic
Vedantra PharmaceuticalsPresente by: Peter DeMuth, Senior [email protected] Poster Title: Interbilayer Crosslinked Multilamellar Vesicles (ICMV): a safe, versatile, and potent vaccine delivery platform
Wyss Institute at Harvard UniversityPresented by: Xi Chen, Postdoctoral [email protected] Title: Digital DNA probes for non-invasive tumor monitoring
7th Annual Massachusetts Life Sciences Innovation Day
46 Poster Presenters
Wyss Institute at Harvard UniversityPresented by: Edward Doherty, Senior Staff Scientist [email protected] Title: Controlled VEGF & IGF delivery from an injectable alginate to create vascu-lar reperfusion in ischemic tissue.
Wyss Institute at Harvard UniversityPresented by:Jonathan Kotula, Postdoctoral [email protected] Title: Programmable Bacteria as Diagnostics of Gut Health
Wyss Institute at Harvard UniversityPresented by:Thomas Valentin, Research [email protected] Title: A rapid pathogen detection device for food contamination
June 3, 2014Harvard Club of Boston
Innovator's Marketplace Exhibitors 47
Innovators’ Marketplace ExhibitorsLife Science Products and Services
